Abpro Holdings, Inc. (ABP)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jin Wook Suk | CEO & Chairman of the Board | -- | -- | 1979 |
| Dr. Robert J. Markelewicz Jr., M.D. | Chief Medical Officer | 483.58k | -- | 1980 |
| Mr. Eugene Y. Chan M.D. | Co-Founder | 250k | -- | 1975 |
Abpro Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 6
Description
Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues. Its platform DiversImmune addresses the antibody therapeutics. The company's product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer. It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema. Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
May 1, 2025 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
April 23, 2025 at 12:00 AM UTC
POS EX: Post-effective amendment filed solely to add exhibits to a registration statement